2Bristor-Myer Squibb. Gatifloxacin (Tequin) :An advanced generation quinolone for the treatment of selected infectious diseases [M] .Glenview: Physicians Scientists Publishing CO, INC, 2000. 47.
3Wish R, Honeybourne D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract[J]. European Respir J, 1999, 14 ( 1 ): 221.
4Ball P, Wilson R, Mandell L, et al. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis: a randomized, double-blind comparison with trovafloxacin[J]. J Chemother 2001,13 (3):288.
5Tillotson G, Zhao X, Drilica K. Fluoroquinolones as pneumococcal therapy: Closing the barn door before the horse escapes [J]. The Lancet infections Disea, 2001, 1(3): 145.
6Drugeon HB, Juvin ME, Bryskier. Relative potential for selection of fluoroquinolone-resistant streptoccus pneumoniae strains by levofloxacin: Comparison with Ciprofloxacin, sparfloxacin and ofloxacin [J]. J Antimicrob Chemother, 1999, 43 (Suppl)C55.
7Sullivan J G, McElroy A, Honsinger RW, et al. A double-blind, randomized study of Safety and efficacy treating community acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin [J]. J Respir Dis,1999, 20 (Suppl) :49.
8Forgarty C, Dowell ME, Ellison WT, et al. A prospective, randomized, double-blind study treating community-acquired pneumonia in hospitalized patients Gatifloxacin VS Ceftriaxone/Clarithromycin [J]. J Respir Dis, 1999, 20 (Suppl): 60.
9Heffelfingers JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. A report from the drugresistant Streptococcus pneumoniae therapeutic working group [J]. Arch Intern Med, 2000, 160 (10) :13
10Chen HJ, Bloch KJ, Maclean JA. Acute eosinophilic hep atitis from trovafloxacin [J]. N Engl J Med, 2000, 342(5): 359.
